News &amp; Updates

The use of oral contraceptive and hormone replacement therapy may put women at heightened risk of stroke, especially within the first year of use, possibly due to immediate changes in haemostatic balance, according to a study.

Number of prior caesarean deliveries tied to complication risk following second-trimester abortion

While induction in the second trimester for abortion or foetal demise can be safely performed for most women with prior caesarean deliveries, the risk of complications is increased for women with two or more prior caesarean deliveries, a study has found.

L-menthol a safe peristaltic alternative to HBB for older adults undergoing EGD

L-menthol can effectively reduce peristaltic grade in older adults scheduled for esophagogastroduodenoscopy (EGD) with a contraindication to hyoscine-N-butylbromide (HBB), a recent study has found.

$Prucalopride offers relief in children with refractory idiopathic constipation$

Prucalopride offers relief in children with refractory idiopathic constipation

Three out of five teens with refractory constipation achieve improvements in bowel movement with prucalopride, while having acceptable side effect profiles, as shown in a small study.

Netarsudil use for glaucoma may cause punctal stenosis

Use of topical netarsudil 0.02% for the treatment of glaucoma results in the development of reversible punctal stenosis, a recent study has found. This inflammation-mediated stenosis can cause tearing and related symptoms and may lead to treatment discontinuation with sufficient severity.

28 Jun 2022

Fatigue persists as lung function improves months after COVID-19 hospitalization

COVID-19 patients remain on the recovery phase 6 months after hospital admission, with persistent fatigue but improving lung function and quality of life, according to a study.

28 Jun 2022

Can green tea extract prevent colorectal adenoma recurrence?

Use of green tea extract (GTE) is well tolerated but does not appear to prevent colorectal adenomas, results of a recent trial have shown.

Updated ASCEMBL results boost asciminib potential for CML

In the week-96 analysis of the phase III ASCEMBL trial, the first BCR::ABL1 STAMP* inhibitor asciminib sustained superiority over bosutinib for individuals with CML-CP** who have failed ≥2 lines of prior tyrosine kinase inhibitors (TKIs).

28 Jun 2022

Tacrolimus-based treatment induces slower response in children with autoimmune liver disease

Patients with paediatric-onset autoimmune liver disease show slower early immunological and biochemical response to a tacrolimus-based treatment as compared with regimens using prednisolone or azathioprine, reports a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN 2022).

Five-test universal HBV screening strategy most cost-effective in China